The potential prognostic utility of salivary galectin-3 concentrations in heart failure

Loading...
Thumbnail Image
File version
Author(s)
Zhang, X
Karunathilaka, N
Senanayake, S
Subramaniam, VN
Chan, W
Kostner, K
Fraser, J
Atherton, JJ
Punyadeera, C
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2019
Size
File type(s)
Location
License
Abstract

Background: Patients with HF are at a higher risk of rehospitalisation and, as such, significant costs to our healthcare system. A non-invasive method to collect body fluids and measure Gal-3 could improve the current management of HF. In this study, we investigated the potential prognostic utility of salivary Galectin-3 (Gal-3) in patients with heart failure (HF). Methods: We collected saliva samples from patients with HF (n = 105) either at hospital discharge or during routine clinical visits. Gal-3 concentrations in saliva samples were measured by ELISA. The Kaplan–Meier survival curve analysis and Cox proportional regression model were used to determine the potential prognostic utility of salivary Gal-3 concentrations. Results: The primary end point was either cardiovascular death or hospitalisation. Salivary Gal-3 concentrations were significantly higher (p < 0.05) in patients with HF who subsequently experienced the primary endpoint compared to those who did not. HF patients with salivary Gal-3 concentrations > 172.58 ng/mL had a significantly (p < 0.05) higher cumulative risk of the primary endpoint compared to those with lower salivary Gal-3 concentrations. In patients with HF, salivary Gal-3 concentration was a predictor of the primary endpoint even after adjusting for other covariates. Conclusions: In our pilot study, HF patients with salivary Gal-3 concentrations of > 172.58 ng/mL demonstrated a higher cumulative risk of the primary outcome compared to those with lower Gal-3 levels, even after adjusting for other variables. Confirming our findings in a larger multi-centre clinical trial in the future would enable salivary Gal-3 measurements to form part of routine management for patients with HF.

Journal Title
Clinical Research in Cardiology
Conference Title
Book Title
Edition
Volume
Issue
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
This publication has been entered into Griffith Research Online as an Advanced Online Version.
Access the data
Related item(s)
Subject
Cardiovascular medicine and haematology
Cardiovascular disease
Galectin-3
Heart failure management
Prognostic biomarkers
Risk stratify
Persistent link to this record
Citation
Zhang, X; Karunathilaka, N; Senanayake, S; Subramaniam, VN; Chan, W; Kostner, K; Fraser, J; Atherton, JJ; Punyadeera, C, The potential prognostic utility of salivary galectin-3 concentrations in heart failure, Clinical Research in Cardiology, 2019
Collections